This site uses cookies in order to provide you with the best possible service

Read our cookie policy Agree

Specialist fields (in extracts)

  • Treatment of prostate- and bladder disease
  • Treatment of kidney- and ureteral calculi
  • Brachytherapy –for treatment of prostate cancer
  • Conservative treatment of tumor patients

Curriculum vitae (in extracts)

1983-1985 Department of Urology at the University Hospital, Klinikum Charlottenburg, FU Berlin
1984 Department of Urology at the University Hospital, Inselspital Bern
1985-1986 Surgical training at Augusta-Krankenanstalten Bochum
Since 1986 Clinic for Urology, Medizinischen Universität Lübeck
8-2-1989 Degree as Specialist for Urology
Since 1991 Senior physician of the Clinic for Urology
11-1994 Habilitation and appointment as private lecturer
14-12-1999 Appointment as C3-Professor of Urology
1995-1999 Member of the collaborative research centre SFB 367 of the DFG
8-1997 Facultative postgraduate training in Specialized Urologic Surgery
4-1998 Appointment as Examiner for „Specialized Urologic Surgery“
11-1998 Professional Qualifications in laboratory testing in Urology
4-1999 Appointment as expert/evaluator in „ Specialized Urologic Surgery “
9-1999 Appointment as project leader for genetic engineered work
2000-2006 Laboratory group leader in the research centre Borstel(Forschungszentrum Borstel)
2000-2005 Board member of the working group „Experimental Urology“ of the DGU
2000-2005 Deputy spokesman of the research focus „Oncology“, Lübeck
2000-2003 Vice Director of the Clinic for Urology Lübeck
2000-2003 Member of the post graduate programme GRK 288 of the DFG
2000-2003 Member of the collaborative research centre SFB 367 of the DFG
Since 2000 Member of the board AUO / Deutsche Krebsgesellschaft (German Cancer Society)
2000-2005 Spokesman in the field of tumor biology, Research Centre Borstel, (Forschungszentrum Borstel)
2001-2003 Member of the Research Committee of the Med. Universität Lübeck
Since 10-2001 Member of the board, Tumor Centre Lübeck (Forschungszentrum Lübeck)
1-2002 Establishment of the EORTC - AUO Data Clearing Centers Lübeck
2002-2003 Board member of the Klinisch-ExperimentellenForschungseinrichtungen – KEF Lübeck (clinical experimental research centre)
Since 2002 Member of the Guidelines Commission of the European Association of Urology (EAU)
2002-2004 Spokesman of the working group „Experimental Urology“ of the DGU
02-2003 Special course in radiation protection brachytherapy
05-2003 Appointment as „Außerplanmäßiger Professor“
Since 1-6-2003 Urologic group practice Bad Schwartau
01-2004 Certification „Prostate Brachytherapy“
Since 01-2004 Consultant for surgical urology at Klinikum Neustadt
1-1-2005 Kassenärztliche (Association of Statutory Health Insurance Physicians) group practice for Urology, Bad Schwartau; affiliated doctor/consultant at Helios Agnes-Karll Krankenhaus, Bad Schwartau
7-6-2005 Certification „men’s doctor cmi“
3-1-2007 Member of the board of the „European School of Urology“
9-5-2007 Additional designation “Andrology”
6-6-2007 Additional designation „medicinal tumor therapy“
Since 03-2008 License to conduct advanced training in “Andrology” 1,5 years License to conduct advanced training in “ Medicinal tumor therapy ” 1 year



With the „LDR-Brachytherapie“ a modern version of radiation therapy has been established which enables patients with locally restricted prostate cancer to maintain their level of quality of life.  The fundamental idea behind this is that the local appliance of the radiation source is able to deliver a high focal dose to the prostate while protecting the surrounding tissue.
 „LDR“ is the English abbreviation for „low dose rate“ and „Brachys“ is translated from the Greek to  „short“. With the LDR-Brachytherapy the tumor is irradiated from a very short distance directly from the inside. During a one hour surgery radioactive iodine-125 „seeds“ are implanted onto the patient – small titanium coated pins of size of a rice grain.
The seeds are implanted into the prostate by an ultrasound guided cannula, inserted via the pelvic floor. The pin sized mini-implants remain permanently in the prostate with a half-life of about 60 days. The carcinoma is targeted specifically by the permanent irradiation while the surrounding organs such as bladder and colon remain protected.
A few weeks before the surgery, the size and shape of the prostate is determined using ultrasound. From this data the required number of seeds is calculated. The intervention is usually performed under general anesthesia. After the insertion of a urinary catheter, an ultrasonic probe (allowing axial and longitudinal imaging) is placed in the rectum. Multiple images are recorded. From these the number and location of seeds is calculated. The physicist calculates the treatment plan on-site.
The real-time or intraoperative method has the advantage that the seeds can be placed very exact. According to the treatment plan a total of 20-30 2mm cannulas are inserted through the skin between scrotum and rectum into the prostate. The tiny (4,5 x 0,8 mm) seeds are inserted (under ultrasound control) through the cannulas to the calculated position, and positioned very precisely. This is done under continuous ultrasound control which enables to adjust the dose coverage at all times.  
Possible attendant symptoms of the seed-implantation include: traces of blood in the urine or seminal fluid, hematoma in the pelvic area, urinary tract-, prostate- or rectum inflammation, increased urge to urinate as well as formation of residual urine. Involuntary leakage of urine is very rare (<1%) and usual only develops after recent surgical peeling of the prostate. Furthermore a radiation induced potency disorder can develop (<10%), however this can be treated with the appropriate medication (Cialis®, Levitra® oder Viagra® ) in most cases.
An essential component is the quick recovery and with this the restoring of activities of daily life and ability work within a few days.

Send request

We speak english, russian, arabic and french

✓ Valid Invalid
✓ Valid Invalid

By requesting a callback, you agree and accept our Privacy Policy

Your Request will be processed by our partner DMU for Helios. Read more about our Cooperation